Tower Research Capital LLC (Trc) Akero Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,859 shares of AKRO stock, worth $104,866. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,859
Previous 15,642
88.12%
Holding current value
$104,866
Previous $366,000
85.52%
% of portfolio
0.0%
Previous 0.01%
Shares
22 transactions
Others Institutions Holding AKRO
# of Institutions
191Shares Held
74.6MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$445 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$399 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$334 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$315 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$295 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.62B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...